125 related articles for article (PubMed ID: 29192326)
1. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y
Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326
[TBL] [Abstract][Full Text] [Related]
2. Emodin Exerts an Antiapoptotic Effect on Human Chronic Myelocytic Leukemia K562 Cell Lines by Targeting the PTEN/PI3K-AKT Signaling Pathway and Deleting BCR-ABL.
Wang CG; Zhong L; Liu YL; Shi XJ; Shi LQ; Zeng L; Liu BZ
Integr Cancer Ther; 2017 Dec; 16(4):526-539. PubMed ID: 27698265
[TBL] [Abstract][Full Text] [Related]
3. Regulation of hTERT by BCR-ABL at multiple levels in K562 cells.
Chai JH; Zhang Y; Tan WH; Chng WJ; Li B; Wang X
BMC Cancer; 2011 Dec; 11():512. PubMed ID: 22151181
[TBL] [Abstract][Full Text] [Related]
4. Targeted disruption of the
Zeng J; Liang X; Duan L; Tan F; Chen L; Qu J; Li J; Li K; Luo D; Hu Z
Acta Biochim Biophys Sin (Shanghai); 2024 Apr; 56(4):525-537. PubMed ID: 38414349
[TBL] [Abstract][Full Text] [Related]
5. Isoalantolactone mediates the degradation of BCR-ABL protein in imatinib-resistant CML cells by down-regulating survivin.
Yin SS; Chen C; Liu Z; Liu SL; Guo JH; Zhang C; Zhang QW; Gao FH
Cell Cycle; 2023 Jun; 22(12):1407-1420. PubMed ID: 37202916
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the mechanism of USP28-mediated IFITM3 elevation in BCR-ABL-dependent imatinib resistance in CML.
Li Z; Xi Y; Tu L; Zhang X; Huang Y; Nie H; Peng C; Chai H; Zeng S; Zheng X; Cheng L
Biomed Pharmacother; 2024 Apr; 173():116315. PubMed ID: 38394852
[TBL] [Abstract][Full Text] [Related]
7. Impaired immunomodulatory function of chronic myeloid leukemia cancer stem cells and the possible mechanism involved in it.
Xishan Z; Xinna Z; Baoxin H; Jun R
Cancer Immunol Immunother; 2013 Apr; 62(4):689-703. PubMed ID: 23180012
[TBL] [Abstract][Full Text] [Related]
8. Characterization of K562 cells: uncovering novel chromosomes, assessing transferrin receptor expression, and probing pharmacological therapies.
Karagiannis TC; Wall M; Ververis K; Pitsillou E; Tortorella SM; Wood PA; Rafehi H; Khurana I; Maxwell SS; Hung A; Vongsvivut J; El-Osta A
Cell Mol Life Sci; 2023 Aug; 80(9):248. PubMed ID: 37578596
[TBL] [Abstract][Full Text] [Related]
9. HNF1A induces glioblastoma by upregulating EPS8 and activating PI3K/AKT signaling pathway.
Yang G; Su F; Han BX; Su HX; Guo CH; Yu SH; Guan QL; Hou XM
Biochem Pharmacol; 2024 May; 223():116133. PubMed ID: 38494066
[TBL] [Abstract][Full Text] [Related]
10. Induction of human chronic myeloid leukemia K562 cell apoptosis by virosecurinine and its molecular mechanism.
Zhang G; Li M; Han S; Chen D; Wang Y; Ye W; Ji Z
Mol Med Rep; 2014 Nov; 10(5):2365-71. PubMed ID: 25189629
[TBL] [Abstract][Full Text] [Related]
11. Tanshinone IIA enhances the inhibitory effect of imatinib on proliferation and motility of acute leukemia cell line TIB‑152 in vivo and in vitro by inhibiting the PI3K/AKT/mTOR signaling pathway.
Teng Z; Xu S; Lei Q
Oncol Rep; 2020 Feb; 43(2):503-515. PubMed ID: 31894340
[TBL] [Abstract][Full Text] [Related]
12. Indirubin, an Active Component of Indigo Naturalis, Exhibits Inhibitory Effects on Leukemia Cells
Yao Y; Li X; Yang X; Mou H; Wei L
Anticancer Agents Med Chem; 2024; 24(9):718-727. PubMed ID: 38347773
[TBL] [Abstract][Full Text] [Related]
13. CRKL but not CRKII contributes to hemin-induced erythroid differentiation of CML.
Guo C; Lv X; Zhang Q; Yi L; Ren Y; Li Z; Yan J; Zheng S; Sun MZ; Liu S
J Cell Mol Med; 2024 May; 28(9):e18308. PubMed ID: 38683131
[TBL] [Abstract][Full Text] [Related]
14. Zinc as a potential regulator of the BCR-ABL oncogene in chronic myelocytic leukemia cells.
Zhu B; Sun L; Li Z; Shang P; Yang C; Li K; Li J; Zhi Q; Hua Z
J Trace Elem Med Biol; 2024 May; 83():127407. PubMed ID: 38325182
[TBL] [Abstract][Full Text] [Related]
15. MiRNA182 regulates percentage of myeloid and erythroid cells in chronic myeloid leukemia.
Arya D; Sachithanandan SP; Ross C; Palakodeti D; Li S; Krishna S
Cell Death Dis; 2017 Jan; 8(1):e2547. PubMed ID: 28079885
[TBL] [Abstract][Full Text] [Related]
16. Transcriptomics-Based Characterization of the Toxicity of ZnO Nanoparticles Against Chronic Myeloid Leukemia Cells.
Alsagaby SA; Vijayakumar R; Premanathan M; Mickymaray S; Alturaiki W; Al-Baradie RS; AlGhamdi S; Aziz MA; Alhumaydhi FA; Alzahrani FA; Alwashmi AS; Al Abdulmonem W; Alharbi NK; Pepper C
Int J Nanomedicine; 2020; 15():7901-7921. PubMed ID: 33116508
[TBL] [Abstract][Full Text] [Related]
17. Targeted degradation of oncogenic BCR-ABL by silencing the gene of NEDD8 E3 ligase RAPSYN.
Sun Y; Wang Y; Liu C; Huang Y; Long Q; Ju C; Zhang C; Chen Y
J Nanobiotechnology; 2024 May; 22(1):247. PubMed ID: 38741123
[TBL] [Abstract][Full Text] [Related]
18. Bcr-Abl regulation of sphingomyelin synthase 1 reveals a novel oncogenic-driven mechanism of protein up-regulation.
Moorthi S; Burns TA; Yu GQ; Luberto C
FASEB J; 2018 Aug; 32(8):4270-4283. PubMed ID: 29533737
[TBL] [Abstract][Full Text] [Related]
19. Cell-penetrating peptide and cationic liposomes mediated siRNA delivery to arrest growth of chronic myeloid leukemia cells in vitro.
Vysochinskaya V; Zabrodskaya Y; Dovbysh O; Emelyanov A; Klimenko V; Knyazev N; Terterov I; Egorova M; Bogdanov A; Maslov M; Vasin A; Dubina M
Biochimie; 2024 Jun; 221():1-12. PubMed ID: 38215931
[TBL] [Abstract][Full Text] [Related]
20. Investigating critical genes and gene interaction networks that mediate cyclophosphamide sensitivity in chronic myelogenous leukemia.
He X; Deng Y; Yue W
Mol Med Rep; 2017 Jul; 16(1):523-532. PubMed ID: 28560425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
